OVERVIEW OF OSTEOPOROSIS
Osteoporosis is a condition in which the amount of bone tissue is so low that the bones easily fracture in response to minimal force. A person with osteoporosis can fracture a wrist or hip from a fall on the ice or receive a broken rib from an affectionate hug (Aloia, 1989) . Osteoporosis leads to physical changes including fractures, severe curvature of the spine, and loss of height which affect body image and self esteem.
The three types of osteoporosis are post-menopausal osteoporosis (Type I), senile osteoporosis (Type II), and secondary osteoporosis. Postmenopausal osteoporo sis (Type I) is directly linked to the decreased production of estrogen that coincides with menopause. It is characterized by an increased bone resorption and primarily affects trabecular bone (Avioli, 1991) , with losses at an accelerated rate estimated at three times the rate of normal loss. Though postmenopausal osteoporosis affects cortical bone loss as well, it is at a lower rate. Fractures associated with Type I osteoporosis typically present within 10 to 15 years after the onset of menopause, and often occur in the lumbar vertebrae, distal radius (Colles' fracture), and other bones containing a large composition of trabeculae (Tolstoi, 1992) .
Senile osteoporosis (Type II) is a second type of primary bone loss resulting from a proportionate, gradual loss of trabecular and cortical bone usually due to decreased bone cell activity accompanyin g aging. Inadequate calcium intake and the decrease in physical activity, common in the elderly years, contribute s to the etiology (Chapuy, 1992) . In contrast to postmenop ausal osteoporosis, senile osteoporosis is experienced equally by both genders with fractures occurring mainly in the hip. This type of disorder predominately afflicts men and women over the age of 70 years (Tolstoi, 1992) .
Secondary osteoporosis can result as a consequence of certain disease states. The most common health conditions include chronic renal disease, hypogonadism, hyperthyroidism, and some forms of cancer. In addition, surgical procedures, such as early oophorectomy in women or subtotal gastrectomy, can lead to bone loss. Some medications, in particular anticonvulsants and corticosteroids, also have toxic effects on bone (Wardlaw, 1993) . One in two women and one in five men will develop osteoporotic fractures. A woman's risk of developing a hip fracture is equal to the combined risk of developing breast, uterine, and ovarian cancer. Yet, in the 1991 National Family Opinion Survey, fewer than 42% of the women surveyed believed that osteoporosis can result from menopause (Jacobowitz, 1993) . This indicates that women need more accurate information related to osteoporosis. called remodeling. The purpose of bone remodeling is to replace older bone that has developed microscopic breaks, called micro fractures, with new bone. Each adult year, 10% to 30% of the skeleton is replaced by remodeling. Remodeling occurs as the osteoclasts appear and dissolve bone. The osteoclastic cells eventually die, leaving a hole in the bone. Osteocytes and osteoblasts then appear. The osteoblasts fill the hole with matrix, and bone is mineralized. Unmineralized matrix is called osteoid. If the osteoblasts do not completely fill the hole, less bone is formed than resorbed at that site. If the osteoblasts fill the hole with extra bone, then bone formation exceeds bone resorption. Over a million remodeling units in the skeleton exist at any given time-1O of these units together have a volume only the size of a pin's head (Aloia, 1989) .
Remodeling balance is a term used to indicate whether extra bone was formed (positive balance) or less bone was formed (negative balance). Because 99% of the body's calcium is in the skeleton, calcium balance actually reflects the gain and loss of bone. Therefore, the difference between bone formation and bone resorption determines whether bone is lost or gained and whether calcium balance is negative or positive (Aloia, 1989) .
BONE LOSS AND BONE GAIN
Women begin life with lower bone mass than men. During the first year of life, the skeleton increases more in relation to body size than at any other time in the life cycle. During childhood, the skeleton increases in mass with the rest of the body (Aloia, 1989) . Under the influence of gonadal hormones (estrogen in women and testosterone in men), a rapid phase of skeletal growth occurs during adolescence. During this rapid phase of growth, the skeleton is not architecturally mature. During young adulthood, the skeleton fills out, and maximal skeletal mass and strength are developed. Thus, bone mass reaches its peak after linear growth (height) has ceased. Indeed, a woman may gain 10% to 15% of her skeletal mass in the reproductive stage of her life cycle. This amount of bone is almost equivalent to the amount lost after menopause. Peak bone mass, the amount present before the onset of bone loss to aging, is a major determinant of bone mass in later life (Aloia, 1989 ).
It appears that the highest attainable peak bone mass is genetically predetermined, but other factors are present. For example, drinking milk in childhood has been associated with higher peak bone mass. Studies have shown that bone mass can be increased through exercise by the mechanical stress placed on the skeleton. Gonadal or sex hormones also play a role in achieving maximal peak bone mass. Studies of women with a history of oral contraceptives, containing a very high estrogen content, suggest that they may be protected against osteoporosis in later life (Aloia, 1989) , Around age 35 to 40 years, a slow loss of bone mass begins in both men and women. Less than 0.5% is lost from the entire skeleton annually. This may be due to the aging process or to less stress being exerted on the skele- Recommended Calcium Intake Osteoporosis Foundation, 1994) . Ensuring an adequate amount of calcium is essential, as it must be present in adequate amounts to allow bone formation to occur. In this way it may help in protecting against osteoporosis. An 8 oz. glass of whole or skim milk, llh ounces of cheddar cheese, and 1 cup of yogurt each contain an estimated 300 mg of calcium, nearly one third of the recommended daily allowance before menopause (National Osteoporosis Foundation, 1994) . Table 1 lists daily calcium recommendations. Some individuals do not like or do not tolerate milk or milk products and prefer to take a calcium supplement. When considering a supplement, one should always look for the amount of elemental calcium-the number of milligrams of pure calcium received. Forty percent of a calcium carbonate tablet is actual calcium. Therefore, a 500 mg tablet of Turns contains 200 mg of calcium. If an individual seeks counseling about the use of calcium supplements, the nurse should first help the client identify sources of diet calcium. If the client's daily diet leaves them 400 mg short of optimal calcium intake, taking two tablets of Turns per day meets the daily requirement. Not all calcium supplements are alike, therefore it is important to teach the client to read labels and to know what they are actually getting. Table 2 outlines the various purified calcium formulations on the market. the calcium percentage in each formulation, and their relative costs (Sit, 1997) .
If 400 mg of calcium per day is needed from a supplement, it is best to divide the dosage. Instead of taking ton as a result of decrease in physical activity (Aloia, 1989) . In addition to the slow rate of bone loss, women experience a rapid rate of loss (2.5% to 3.5% per year) beginning at menopause. This continues for 5 to 10 years and then reverts to the earlier, slower loss. Thus, by age 70 women again lose bone mass at the same slow rate as men (Aloia, 1989) .
OSTEOPOROSIS RISK FACTORS
The following factors have been identified by the National Osteoporosis Foundation (1994) as factors that place individuals at a greater risk for osteoporosis: • Age-The older the person is, the greater the risk of osteoporosis. Bones become less dense and weaker as individuals age. • Sex-The chances of developing osteoporosis are greater for women. Women have less bone tissue and lose bone more rapidly than men because of the changes involved in menopause. • Race-White and Asian women are more likely to develop osteoporosis than black and Hispanic women, although all women are at risk. • Bone structure and body weight-Small boned and thin women are at a greater risk. • Menopause-Normal or early menopause (brought about naturally or because of surgery) increases risk for developing osteoporosis. In addition, women who stop menstruating before menopause because of conditions such as anorexia or bulimia, or because of excessive physical exercise, also may lose bone tissue more rapidly than normal. • Lifestyle-Smoking, consuming too much alcohol, taking an inadequate amount of calcium, or getting little Of no weight bearing exercise increases the chances of developing osteoporosis. • Medications and disease-Osteoporosis is associated with certain medication use (e.g., cortisone like drugs), and is a recognized complication of a number of health conditions including endocrine disorders, rheumatoid arthritis, and immobilization. • Heredity-Susceptibility to fracture may be, in part, hereditary. Young women whose mothers have a history of vertebral fractures also seem to have reduced bone mass.
PREVENTING OSTEOPOROSIS Diet
Many people mistakenly believe that they do not need to worry about developing osteoporosis until they are older. Because peak bone mass develops in the younger years, it is critical to educate younger women during the time interventions could prevent or reduce complications from osteoporosis . When more bone mass is accumulated, the individual can stand to lose more bone without complications . Adequate calcium and vitamin D intake and exercise are critical in the bone modeling and remodeling process and are determinants of bone strength in later years.
Recent studies indicate that many adults get only half or less of their daily calcium requirement (National both tablets at the same time, it is better to take them at separate times, or take one half tablet four times per day. Following this advice decreases the constipation that can occur with calcium supplementation and also lowers the risk of kidney stones in susceptible individuals. Clients with a history of kidney stones are not good candidates for calcium supplementation (Sit, 1997) . Calcium carbonate is an antacid and can be harmful if not taken correctly. Three Turns or Sodium Free Rolaids as a source of calcium can neutralize stomach acid. Because stomach acid is needed to properly digest protein and carbohydrates in food, daily large intakes of calcium carbonate tablets can lead to poor nutrition. The stomach can counteract the antacid effects of calcium carbonate by secreting more acid than normal. This effect, called "acid rebound," can be potentially painful and irritating to clients with ulcers or risk for ulcers. Thus, it is critical to provide education about the adverse effects that can be caused by excessive calcium supplementation. The best advice is to get as little calcium from supplements as possible, and to increase the calcium in the diet (Sit, 1997) .
Young women are not always receptive to the idea that they should make milk products a regular part of their diet. They may view milk as a high calorie food or may simply dislike it. Nurses should provide information about how to obtain adequate calcium from other sources besides dairy products and also should make certain that clients are aware of products available for lactose intolerant individuals. Calcium fortified orange juice has just as 184 much calcium as milk per glass. Other foods that contain high amounts of calcium are low fat yogurt, black strap molasses, tofu, kale, and rhubarb. English muffins and biscuits have more calcium than other breads because they are usually made with baking powder which contains calcium. Nonfat powdered milk can be added to any dish. Table 3 provides a short list of non-dairy foods that help provide dietary calcium.
Vitamin D is necessary for calcium absorption. The body manufactures vitamin D as a result of exposure to sunlight, and it is obtained from vitamin D enriched milk products. Recommendations for vitamin D supplementation suggest 400 units per day (National Osteoporosis Foundation, 1994) . However, vitamin D is the most potentially toxic of all vitamins (Sizer, 1994) . Most adults would not be considered candidates for vitamin D supplements. However, housebound or institutionalized individuals or those who work at night may incur (over years) a vitamin D deficiency leading to deficiency of calcium severe endugh to damage their bones. Adults who can tolerate milk receive a source of both vitamin D and calcium. Individuals with sensitivities to milk need to seek alternative calcium sources and make a point of spending time outdoors (Sizer, 1994) .
Certain medications can affect the bioavailability of calcium . In particular, several commonly used medications, such as isoniazid for the treatment of pulmonary tuberculosis, corticosteroids, the antibiotic tetracycline, and aluminum containing antacids, can increase urinary Adapted from Non-dairy Sources of Calcium. <http://elaine. teleport.com/-amrta/calcium.html> (1997, May 22) Calcium Content in Some Selected Non-Dairy Foods ty diminishes, osteoclast activity increases and bone is lost. In addition, bone loss is caused by age related calcium malabsorption, which stimulates hyperparathyroidism (Moussa, 1997 (2) Walnuts Whole wheat flour calcium excretion and contribute to or accelerate bone loss (Jacobowitz , 1993) . Alcohol use/abuse is associated with adverse effects on bone mass. Alcohol is believed to depress bone formation by directly reducing osteoblastic activity.Dietary intakes of heavy drinkers often lack essential nutrients which can result in diminished intestinal absorption of calcium. Finally, alcohol intoxication gives rise to social situations that favor accidents and falls (Laitinen, 1991) .
Smoking is another risk factor for osteoporosis. Heavy smokers show significantly lower bone mineral density than do nonsmokers. Smokers also tend to maintain a lean body weight, experience menopause an average of 1.2 years earlier, and show an accelerated rate of postmenopausal bone loss (Jensen, 1985) . The increased prevalence of women smokers over the past 20 years is suspected to be a contributing factor to the doubling rates of hip fractures in women (Law, 1991) .
Exercise
Weight bearing exercise is required for bone formation through out life. Muscular activity, gravity, and mechani cal loading stimulate bone cells to grow, leading to an increase in bone mass. Disuse is shown to result in bone loss. Sedentary women have less bone mass than age matched exercising women. However, excessive exercise in women may lead to exercise induced amenorrh ea and subsequent redu ced bone mass. Postmenopausal women can increase their bone density with a moderate exercise program, especially in combination with adequate calcium intake and estrogen replacement therapy (ERT) (Chung, 1996) .
Caution is required when advising people about exercise. Elderly individual s who have not been regular exercisers need to begin slowly with a moderate walking program or some other type of weight bearing exercise, combined with muscle strengthening. Most elderly people also need education concerning fall prevention.
Estrogen
Estrogens have direct and indirect effects on bone resorption. Estrogen acts indirectly on bone resorption by interfering with parathyroid hormone, thereby suppressing bone resorption . When estrogen levels are high, parathyroid hormone levels are diminished and normal bone structure is maintained . Serum calcium levels must be maintained within a narrow range of normal 94.5-5.5 mmol/L for normal cardiac and nervous system functioning. When serum calcium levels are decreased, parathyroid hormone is activated, causing increased serum calcium levels. Method s by which parathyroid hormone increases serum calcium levels are achieved through stimulation of intestinal absorption of calcium, decreased renal excretion of calcium in the renal tubule, and resorption of calcium from bone (Schlenker, 1993) .
Estrogen acts directly on bone resorption by stimulating bone accretion through osteoblast estrogen receptors. Estrogen receptor stimulation inhibits cytokine production, which is involved in bone remodeling and resorption . During menopause, when estrogen availabili- Sources: ·PDR Generics (1995) . tBurger ). §Thacker (1996 ). tPilerand (1995 ). · ·Callens (1996 .
Benefits
Nearly 60% Women's decisions about hormone replacement therapy (HRT) are complicated and should be individualized. Nurses need to provide comprehensive and accurate information to women about possible adverse reactions, risks, and benefits of HRT. Women who have had a hysterectomy may take unopposed estrogen because they will not be at risk for endometrial cancer. However, women with uterus intact need to add progesterone (medroxyprogesterone acetate [MPA]) to stimulate release of endometrial tissue.
A rapid growth in scientific literature documenting the risks and benefits of HRT has occurred. HRT is recommended for women at high risk for osteoporosis. Studies have concluded that HRT reduced approximately 60% of hip and wrist fractures if HRT was initiated within a few years of menopause (PDR Generics, 1995) . Women with oophorectomies (surgical removal of ovaries) prior to age 50 are especially at risk for osteo-186 porosis . Known risks and benefits of HRT are presented in Table 4 . Women need to be assessed for family and personal histories to weigh individual risks and benefits. Table 5 presents potential adverse reactions to estrogen and MPA.
Not all women are candidates for HRT. Contraindications for estrogen include pregnancy, breast cancer, estrogen dependent neoplasia, undiagnosed genital bleeding, active thrombophlebitis, or thromboembolic disorders. Contraindications for MPA include thrombophlebitis, thromboembolic disorders, cerebral apoplexy, liver dysfunction, breast or genital cancer, undiagnosed vaginal bleeding, incomplete abortion, or pregnancy (PDR, 1997) .
HRT is available in several forms and dosages (Table  6) . Women need to be given the smallest dosages of HRT possible, and counseled about proper administration.
For women requiring both estrogen and MPA, it is commonly recommended to administer a continuous regimen using 0.625 mg of conjugated estrogens and 2.5 mg of MPA together every day without a break:. After approximately 6 months , most women taking estrogen and a progesterone continuously no longer experience periodic bleeding, the major barrier to compliance with the cyclic regimen. In the first year of HRT, the woman experiences a 3% to 5% increase in bone density. Gains are not as dramatic in the second year of therapy because much of the damage has been corrected (Carr, 1993) . Although most women starting HRT (combination therapy of estrogen and progestin) are entering menopause or not far beyond, some women in their 60s and 70s benefit by starting HRT. A woman of this age who has not had bone densitometry should be tested. If bone density is more than 1 standard deviation below the reference mean, the woman is a candidate for HRT. Small increases in bone density in an elderly woman may lead to large decreases in fracture risk. One group of investigators calculated that in an 80 year old woman, a 14% increase in bone density reduces hip fracture risk by 50% .
The question of when to stop estrogen therapy is best answered by the woman working with the health care provider. For example, an individual who takes HRT for 10 years delays reaching the fracture threshold for 10 years. Stopping therapy results in the loss that would have otherwise occurred just after menopause. Therefore, experts recommend continuing therapy for at least 10 years, unless an illness or contraindication intervenes. This also maximizes the cardiovascular benefits of estrogen (Carr, 1993) .
Some controversy exists about the use of estrogen replacement therapy because of the potential for increased risk of breast cancer. Prolonged use of estrogen (10 to 15 years) along with aging may increase the risk of breast cancer by 10% to 30% (Hulka, 1990) . A recent prospective study explains a potential link among estrogen levels, breast cancer risk, and skeletal status. Subjects with bone density at the top quartile had more than a twofold greater risk of breast cancer than matched females who had bone density at the lowest quartile . These data suggest that a higher lifetime estrogen exposure, beneficial to bone, would be detrimental to breast cancer risk (Moussa, 1997) .
OTHER PHARMACOTHERAPEUTIC APPROACHES
Women hesitant about HRT have turned to supplementing their diets with phytoestrogens. Phytoestrogens are estrogenic substances derived from a diverse group of plants, including soybeans, flaxseed , alfalfa. garlic, parsley, wheat, rice, carrots, potatoes, dates, pomegranates, cherries, apples, and coffee (Environmental Estrogens, 1997) . It is important to note that there is wide variation in the amount of phytoestrogens that plants contain, and that estrogens produced by plants are not benign. In fact, large doses of phytoestrogens can promote abnormal cell growth in the uterine lining just the same as unopposed estrogen taken in the traditional form. Clinical studies are underway to measure the effects of phytoestrogens on perimenopausal women. This is an area that may offer APRIL 1998, VOL. 46, NO.4 promising benefits. However, due to the highly individualized nature of diet therapy, the nurse may want to wait until results of clinical studies become available before offering any definitive direction in this area. Although HRT is the most common therapy for osteoporosis, other methods are now available. Salmon calcitonin is used as an alternative therapy to estrogen when the latter is contraindicated or not well tolerated. It is a peptide hormone which inhibits bone resorption by acting directly on the osteoclasts. The analgesic effects of intranasal calcitonin have proven to be successful in reducing the skeletal pain associated with osteoporosis, although the mechanism for this pain relief is unclear (Kessenich, 1996; Wardlaw, 1993) . Intranasal calcitonin (Miacalcin) was approved by the Food and Drug Administration (FDA) in the fall of 1995 (Kessenich, 1996) . It is administered in daily doses of 200 ill per day. Practitioners should instruct clients to administer one puff (0.09 mL =200 ill) in one nostril and to alternate nostrils every day. Several studies have shown this dosage to be safe, well tolerated, and effective in preventing spinal bone loss in elderly individuals (Cranney, 1995; Martorana, 1995) .
Salmon calcitonin is primarily used when HRT is not recommended or it can be used for its analgesic effect with respect to bone pain. For poorly understood reasons, the increase in bone density brought about by calcitonin administration may be transient (Gruber, 1984) . It is believed that resistance to calcitonin may develop over time. In an attempt to prevent the development of resistance, several investigators administer calcitonin in a cyclic manner (i.e., 3 months on, 1 month off). These regimens are based on theoretical, not yet proven strategies. Calcium supplementation at a dose of.l,OOO mg/d, and vitamin D (400 ill/d) should be given during calcitonin treatment (Moussa, 1997) .
Fosomax (alendronate sodium) is FDA approved for treatment of osteoporosis. Fosomax is an arninobisphosphonate drug that inhibits osteoclast activity by binding to hydroxyapatite, a bone matrix mineral inhibiting bone resorption. Bone resorption is reduced, which allows increased bone accretion and ultimately reduced occurrence of fractures and progressive bone growth. Fosomax is intended for postmenopausal women with osteoporosis not receiving HRT. It is not yet known if aldendronate is safe or effective in other populations, such as children or premenopausal women. Although a small number of women in the initial clinical trials were receiving HRT, it is not yet recommended that women on HRT receive concomitant alendronate due to a lack of scientific or clinical support (Alendronate, 1997) .
Clinical studies have shown that women who took Fosomax had decreased bone resorption as early as 1 month. Increases in bone mass density were evident as early as 3 months and continued throughout 3 years of treatment. The drug provides women unable to take estrogen with an alternative treatment to help with maintaining bone mass (Merck and Co., 1995) . A bone density test, dual energy X-ray absorptiometry (DEXA), that indicates a bone mineral density of at least two standard deviations below young normal and/or a history of osteoporotic fracture should precede a prescription for alendronate.
Gastrointestinal irritation is the most common side effect of alendronate (Thacker, 1996) . Other side effects include musculoskeletal pain, constipation, or diarrhea (Alendronate, 1997). The optimal bioavailability of alendronate is best if taken 30 minutes before breakfast. Absorption of the drug is significantly reduced if taken with liquids other than water. To reduce esophageal irritation, individuals should take the drug with 6 to 8 oz. of water, and should not lie down for 30 minutes following administration. Calcium supplements, antacids, or other drugs should be taken at least 30 minutes following alendronate. For women taking doses of alendronate > 10 mg/day, the use of aspirin containing drugs may be associated with increased gastrointestinal problems (Alendronate, 1997) .
Sodium fluoride has been used for more than 30 years in Europe for the treatment of osteoporosis (Kessenich, 1996) . Fluoride stimulates bone formation by increasing the number of osteoblasts. Sodium fluoride has been found to increase vertebral bone density. However, earlier studies revealed that bone developed during fluoride therapy was more brittle and lacked strength and elasticity (Riffe, 1992) .
The United States has historically viewed sodium fluoride treatment unfavorably (Kessenich, 1996) due to the numerous side effects (e.g., gastric irritation and lower extremity pain) brought about by its use, and the fact that it requires simultaneous supplementation to prevent impaired bone mineralization (Wardlaw, 1993) . However, a recent study compared a treatment group which received slow release sodium fluoride (25 mg) and calcium citrate (400 mg) twice a day. Findings demonstrated a 20% increase in spinal bone density, a 10% increase in femoral bone density, and a substantial decrease in the number of new spinal fractures over a 4 year period. The treatment group also noted relatively few side effects. This study has prompted the develop- APRIL 1998, VOL. 46, NO.4 ment of a slow fluoride encapsulated in a wax coat which enables it to pass through the gastrointestinal tract without causing discomfort (Kessenich, 1996) . If and when the FDA approves sodium fluoride, it will be in a dosage of 25 mg twice a day, along with 800 mg of calcium in 14 month cycles (12 months on followed by 2 months off) (Pak, 1995) .
OSTEOPOROSIS RISK ASSESSMENT
Just as risk for stroke or heart attack from blood pressure or cholesterol measurements can be assessed, the risk for fracture in an individual can be determined with bone density testing. In fact, the relationship between bone density and fracture risk is stronger than the widely accepted relationship between cholesterol and coronary artery disease (Ettinger, 1996) .
Bone density can be measured by various techniques such as X-ray absorptiometry, radiogrametry, dual X-ray absorptiometry (DXA), and quantitative computed tomography. However, dual X-ray absorptiometry has rapidly become the standard for clinical testing. It is highly reproducible and allows measurements of bone density in both the spine and the hip, two clinically relevant sites in osteoporosis. The bone density test places individuals in three general diagnostic categories: • Normal bone density is a bone density not more than 1 standard deviation below the young adult mean (Tscore above -1). • Osteopenia (low bone mass) is when the bone density lies between -1 and -2.5 standard deviations below the young adult mean (T-score between -1 and -2.5). • Osteoporosis is when the bone density is more than 2.5 standard deviations below the young adult mean (Tscore < -2.5, or the presence offragility fractures irrespective of the bone density) (Moussa, 1997) . Each decrease in T-score unit approximately doubles the fracture risk for the individual (Moussa, 1997) .
The scan takes only about 5 minutes and with an average cost of $100 to $300. This test is believed to be a better predictor of long term risk for osteoporosis than similar tests. The DEXAlDXA exposes the client to 1I20th the radiation associated with a chest X-ray film. Therefore, it is considered to be a very low risk procedure (Carr, 1993) . The information obtained from bone density testing helps women in their decisions related to estrogen therapy or other treatments. If the bone density is not low, the woman might consider having the test repeated in about 2 years (Carr, 1993) .
The development of osteoporosis education and screening programs in the worksite could prove to be the best way to reduce the incidence of osteoporosis in the United States. Increased knowledge about osteoporosis has been shown to produce lifestyle changes such as increases in calcium intake and increased exercise (Ali, 1992) . Therefore, one important aspect of nursing practice is to implement educational programs or develop materials which increase general knowledge levels about the disease. Risk assessment can be used in conjunction with educational programs or on an individual basis. The fA 50 year old white female who has never taken estrogen weighs 120 lb. Her mother suffers from severe osteoporosis. She has no other significant risk factors for osteoporosis. Adapted from Moussa (1997) .
Questionnaire criteria* Case examplet

Program Example
A worksite screening program recently implemented at Fannie Mae is a joint project between Fannie Mae and the Bone Health Center of Bethesda, MD. It was funded in part through an educational grant from Merck & Co. The campaign included on site educational workshops to increase disease awareness, individual bone health assessments, bone density testing, and health care provider referrals to develop intervention and treatment plans. As a result of the screening, an unexpectedly large percentage of younger women screened were found to have significantly lower bone mass than expected. Seventy percent of women over 50 were at high risk for developing osteoporosis, and 54% of the 178 women participating in the program had more bone loss than normal. Additionally, 74% were not getting the recommended daily allowance of calcium. Fannie Mae intends to track the participants' progress resulting from the intervention program and to expand the program to its regional offices (Fuller, 1996) . This type of approach to osteoporosis prevention could help identify thousands of individuals at risk and help them take preventive measures before significant bone loss has occurred.
The use of biochemical markers of bone formation or bone resorption outside research studies still is limited by a large diurnal variation or the poor reproducibility (15% to 20%) of most markers. The lack of predictive value of these markers makes their use questionable. Consequently, no established guidelines exist for the use of these biochemical markers in diagnosing or monitoring clients with osteoporosis (Delmas, 1996) .
CONCLUSION
Osteoporosis is a debilitating disease. Nothing can be done to restore the integrity of the skeleton or to restore an individual's mobility once it is lost. Prevention is the key to healthy bone and enhanced quality of life. Women must be educated about the importance of adequate calcium intake and a healthy lifestyle which includes regular weight bearing exercise. They need information about the risks and benefits associated with estrogen therapy so they can make a well-informed decision regarding its use. In addition, women need current recommendations about newly available therapies. Assessing risk factors among the work force and implementing screening programs will help identify at risk individuals before irreparable skeletal damage is done. 3. Add 4 points if ever been 20 + 0 = 20 treated for or has rheumatoid arthritis "Score" questionnaire (Table 7) is a screening tool recently developed by Lydick (1996) . The questionnaire, which is intended for use only in postmenopausal women age 50 and higher, helps to identify individuals most likely to benefit from bone density evaluation. Clients scoring 6 or higher are referred for densitometry. As more tools like this are developed and modified for use in different populations, nurses will be able to use them to help reduce unnecessary referrals. However, clinical judgement should always prevail.
Does
When the nurse practitioner incorporates osteoporosis screening into an individual assessment, the first step is to obtain a complete health history, physical and gynecological examinations. If indicated, bone density tests may be ordered and the client may need to be referred for more extensive laboratory tests to rule out other bone related diseases.
Some tests used to distinguish primary vs. secondary osteoporosis include a complete blood count, serum chemistry group (chem 20), urinalysis, and thyrotropin.If further testing is needed, the clinician may order erythrocyte sedimentation rate, serum parathyroid hormone concentration, serum 25-hydroxyvitaminD concentration, 24 hour urinary calcium excretion, serum/urine protein electrophoresis, or bone marrow exarninationlbiopsy (Moussa, 1997) . Understanding and Preventing Osteoporosis.
1.
2.
3.
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Osteoporosis is a condition in which the amount of bone tissue is so low that the bones easily fracture in response to minimal force.
Osteoporosis affects more than 25 million Americans, 80% of whom are women. Because osteoporosis is a "silent disease" that can progress undetected for decades, early screening can identify women at risk which may help avert the escalation of this healthproblem.
Risk factors include older age; female; white or Asian ethnicity; normal or early menopause; lifestyle factors including smoking, excessive alcohol intake, little or no exercise, taking inadequate amounts of calcium; medications and disease; and heredity.
Prevention efforts need to be directed toward education related to the need for adequate dietary calcium and the need for weight bearing exercise. Health care providers should develop methods for screening clients to determine whether they are at risk and need a bone density test.
CE MOD U L E
Understanding and Preventing Osteoporosis
This issue of the AAOHN JOURNAL contains a Continuing Education Module on "Understandinq and Preventing Osteoporosis." 1.2 contact hour of continuing education credit will be awarded by AAOHN upon successful complet ion of the posttest and evaluation.
A certificate will be awarded and the scored test will be returned when the following requirements are met by the participant: 1) The completed answer sheet is received at AAOHN on or before March 31, 1999;  (2) A score of 70% is achieved by the participant; (3) The answer sheet is accompanied by a $10 processing fee. Expect up to 6 weeks for delivery of the certificate.
Upon completion of this lesson, the occupational health nurse will be able to:
1. Identify the risk factors for and types of osteoporosis.
2. Compare the effectiveness of interventions to reduce the risk of osteoporosis : diet, exercise, HRT, and other therapies.
3. Discuss the role of the nurse in worksite programs to prevent osteoporosis.
AAOHN is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center 's Commission on Accreditation. Alabama provider number ABNP0063. California provider number CEP9283 . Louisiana provider number LSBN3.
Contact hour credits received for successful complet ion of the posttest and evaluation may be used for relicensure, certification, or re-certification.
